Nanox Imaging Ltd. (NASDAQ: NNOX) has entered into a distribution agreement with SOLME RC, S.A., a Costa Rica-based medical equipment distributor, to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement grants SOLME responsibility for marketing, distribution, installation, training, and ongoing technical support in Costa Rica.
SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services. This relationship positions Nanox to penetrate Costa Rica's public healthcare system, which could accelerate adoption of the Nanox.ARC once regulatory approvals are secured. Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration.
Costa Rica represents Nanox's third Latin American market this year, following Argentina and Peru. This expansion underscores the company's strategic focus on emerging markets where access to advanced medical imaging is often limited. By entering Costa Rica, Nanox continues to execute its vision of driving the world's transition to preventive health care through affordable, scalable imaging solutions.
The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. It is part of a broader ecosystem that includes Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
This distribution agreement matters because it signals Nanox's ability to replicate its commercialization model across new geographies. Latin America faces significant challenges in healthcare access, with many regions lacking sufficient imaging infrastructure. By partnering with local distributors like SOLME, Nanox can navigate regulatory landscapes and establish a presence more efficiently than going it alone. The proof-of-concept registration period allows for clinical validation and relationship building with the CCSS, potentially leading to broader adoption.
For investors, this deal represents tangible progress in Nanox's global expansion strategy. Each new market adds potential revenue streams and validates the company's technology and business model. The stock (NASDAQ: NNOX) may react positively to this news as it demonstrates execution against stated goals. Moreover, the agreement highlights the growing demand for affordable 3D imaging solutions in emerging markets, a niche that Nanox is well-positioned to fill.
To view the full press release, visit https://ibn.fm/C77lJ. For the latest news and updates relating to NNOX, visit the company's newsroom at http://ibn.fm/NNOX.
